Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Events

Events

Thumbnail
August 08, 2022

World Lung – Toxicity scuppers Amgen’s first-line lung hopes

In the Kras plus checkpoint inhibitor race it looks like advantage Mirati, for now.

Thumbnail
July 28, 2022

Go or no go? J&J’s bispecific FDA first

Pdufa decisions also beckon for Amicus, Acadia and Bluebird.

Article image
Vantage logo
June 07, 2022

Asco 2022 – PMV’s therapeutic window slams shut

Liver and other toxicities threaten to scupper another attempt to reactivate mutated p53, the “guardian of the genome”.

Article image
Vantage logo
June 07, 2022

Asco 2022 – looking beyond Enhertu in Her2-low cancer

Article image
Vantage logo
June 07, 2022

Asco 2022 – a novel target rounds out Daiichi’s triple

Article image
Vantage logo
June 06, 2022

Asco 2022 weekend story roundup

Article image
Vantage logo
June 06, 2022

Asco 2022 – Adicet works hard to avoid the allo Car-T scenario

Long-awaited gamma-delta Car-T data sees the response rate fall to 20% at six months, but when is a relapse not a relapse?

Article image
Vantage logo
June 06, 2022

Asco 2022 – the spirit of Rova-T struggles to live on

DLL3, a pariah antigen after the implosion of Abbvie’s Rova-T, holds the interest of a handful of industry players.

Article image
Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Another strong readout could redefine how Her2-negative breast cancer is treated, though a declared victory in triple-negatives is less clear.

Article image
Vantage logo
June 05, 2022

Asco 2022 – investors clutch at the Tigit straws

Roche’s SCLC study is an unmitigated disaster, but investors holding out for success in NSCLC are thrown a crumb of comfort.

Article image
Vantage logo
June 05, 2022

Asco 2022 – Carvykti casts a long shadow

Arcellx, Gracell and Oricell work hard to prove that there is still space for new Car-T therapies in multiple myeloma.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 12, 2022

Q2 Roundup Infographic

August 10, 2022

Q2 Roundup eBook

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.